AMX0035 Shows Positive Progress in Wolfram Syndrome Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2026
0mins
Source: Newsfilter
- Clinical Trial Results: AMX0035's Phase 2 HELIOS trial results at Weeks 24 and 48 indicate sustained improvement in pancreatic beta cell function, as evidenced by C-peptide response tests, suggesting a potential shift in disease progression.
- Good Safety Profile: The latest peer-reviewed data confirm that AMX0035's safety aligns with prior clinical findings, with all reported adverse events being mild or moderate, and no serious adverse events, bolstering confidence in its therapeutic potential.
- FDA Collaboration Progress: Amylyx is collaborating with the FDA to initiate a Phase 3 clinical trial for Wolfram syndrome, aiming to further validate AMX0035's efficacy and safety, demonstrating the company's commitment to future treatment options.
- Positive Patient Feedback: Qualitative interviews with participants reveal significant improvements in diabetes and vision issues, reflecting AMX0035's potential to enhance quality of life, which may attract increased investor interest.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMLX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMLX
Wall Street analysts forecast AMLX stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 14.220
Low
15.00
Averages
21.67
High
28.00
Current: 14.220
Low
15.00
Averages
21.67
High
28.00
About AMLX
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on four investigational therapies across several diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome, AMX0114 in amyotrophic lateral sclerosis (ALS), and AMX0318 in PBH and other rare diseases. AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide and AMX0318 is a novel GLP-1 receptor antagonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AMX0035 Shows Positive Progress in Wolfram Syndrome Trial
- Clinical Trial Results: AMX0035's Phase 2 HELIOS trial results at Weeks 24 and 48 indicate sustained improvement in pancreatic beta cell function, as evidenced by C-peptide response tests, suggesting a potential shift in disease progression.
- Good Safety Profile: The latest peer-reviewed data confirm that AMX0035's safety aligns with prior clinical findings, with all reported adverse events being mild or moderate, and no serious adverse events, bolstering confidence in its therapeutic potential.
- FDA Collaboration Progress: Amylyx is collaborating with the FDA to initiate a Phase 3 clinical trial for Wolfram syndrome, aiming to further validate AMX0035's efficacy and safety, demonstrating the company's commitment to future treatment options.
- Positive Patient Feedback: Qualitative interviews with participants reveal significant improvements in diabetes and vision issues, reflecting AMX0035's potential to enhance quality of life, which may attract increased investor interest.
See More
Amylyx Pharmaceuticals Q1 2026 Earnings Call Insights
- Clinical Trial Progress: In Q1 2026, Amylyx Pharmaceuticals randomized and dosed the last participant in the Phase III LUCIDITY trial, marking a significant milestone with top-line data expected next quarter, which will lay the groundwork for future drug commercialization.
- Accelerated Commercial Readiness: The company is actively advancing its NDA preparations, having begun drafting relevant sections, and plans to launch avexitide in 2027, reflecting a strong commitment to market demand and positive revenue outlook.
- Market Education Initiative: Amylyx plans to launch a disease state education campaign for PBH this summer to enhance market awareness, while strengthening marketing and commercial operations through key hires, which is expected to help the company secure a competitive position in the market.
- Strong Financial Position: As of the end of Q4, the company reported $279.8 million in cash and marketable securities, sufficient to fund operations into 2028, despite operating expenses of $43.8 million, indicating ongoing investment in clinical development to drive avexitide's commercialization.
See More
Amylyx Pharmaceuticals to Report Q1 2026 Financial Results on May 7
- Earnings Report Schedule: Amylyx Pharmaceuticals is set to release its Q1 2026 financial results on May 7, 2026, reflecting the company's ongoing commitment to transparency and investor communication.
- Management Conference Call: The senior management team will host a conference call at 8:00 a.m. ET to discuss the financial results and other company updates, which is expected to attract significant attention from investors and analysts.
- Participation Details: Investors can join the call by dialing +1 (888) 880-3330 for U.S. and Canada or +1 (646) 357-8766 for international participants, ensuring they call at least 10 minutes prior to the start time for smooth access.
- Webcast and Replay: The call will be available via live audio webcast under the “Events and Presentations” section of the company’s website, with a replay accessible for 90 days post-event, enhancing investor access to information.
See More
Halper Sadeh LLC Investigates Amylyx Management for Fiduciary Breaches
- Shareholder Rights Protection: Halper Sadeh LLC encourages shareholders of Amylyx Pharmaceuticals to contact the firm to discuss their rights and options, emphasizing the importance of timely action to protect shareholder interests.
- Legal Fee Arrangement: The firm commits to handling cases on a contingent fee basis, meaning shareholders will not incur any out-of-pocket legal fees or expenses, thereby lowering the barrier for shareholder participation.
- Corporate Governance Reforms: Long-term shareholders of Amylyx stock may have the opportunity to seek corporate governance reforms, fund returns, or court-approved financial incentive awards, aimed at enhancing transparency and accountability, ultimately increasing shareholder value.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide, focusing on combating securities fraud and corporate misconduct, with attorneys playing a crucial role in implementing corporate reforms and recovering funds for defrauded investors, showcasing their expertise in protecting investor rights.
See More
Amylyx Completes Last Participant Enrollment in LUCIDITY Trial for Avexitide
- Trial Enrollment Completion: Amylyx announced that the last participant has been randomized and dosed in the LUCIDITY trial, which enrolled a total of 78 participants, marking a significant milestone with topline data expected in Q3 2026, and a potential commercial launch of avexitide anticipated in 2027 if approved.
- Clinical Trial Design: The LUCIDITY trial is a 16-week, multicenter, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy of avexitide in reducing Level 2 and Level 3 hypoglycemic events in adults post-Roux-en-Y gastric bypass surgery, aligning with FDA-agreed primary outcomes.
- Early Data Support: Previous Phase 1 and Phase 2 trials demonstrated statistically significant reductions in hypoglycemic events with avexitide, indicating its potential to improve patient quality of life and address the urgent need for effective treatments in post-bariatric hypoglycemia.
- Urgent Market Need: Post-bariatric hypoglycemia (PBH) affects approximately 8% of patients who undergo weight-loss surgery, highlighting a significant unmet medical need; the development of avexitide could not only fill this gap but also alleviate the healthcare burden associated with this chronic condition.
See More
Amylyx Pharmaceuticals Updates on Avexitide LUCIDITY Trial Progress
- Trial Progress: Amylyx Pharmaceuticals' LUCIDITY trial is nearly fully enrolled and expects to release top-line results for avexitide in Q3; this 16-week randomized, placebo-controlled study aims to evaluate the drug's efficacy in treating post-bariatric hypoglycemia, highlighting the company's potential in an area lacking approved therapies.
- Drug Mechanism and Market Need: Avexitide, as a first-in-class GLP-1 receptor antagonist, targets approximately 160,000 U.S. patients suffering from post-bariatric hypoglycemia, with prior trials demonstrating significant reductions in hypoglycemic events and supporting its FDA Breakthrough Therapy designation, underscoring its market relevance.
- Efficacy and Data Support: In a Phase II trial, avexitide achieved a 64% reduction in hypoglycemic events at the highest tested dose, with a p-value of 0.003, showcasing its clinical effectiveness and bolstering investor confidence in the drug's potential.
- Future Development Plans: Amylyx is also pursuing a long-acting GLP-1 receptor antagonist, AMX0318, and has reported positive signals in its Wolfram syndrome program, indicating the company's strategic commitment to expanding its product pipeline and addressing unmet medical needs.
See More
AMX0035 Shows Positive Progress in Wolfram Syndrome Trial
- Clinical Trial Results: AMX0035's Phase 2 HELIOS trial results at Weeks 24 and 48 indicate sustained improvement in pancreatic beta cell function, as evidenced by C-peptide response tests, suggesting a potential shift in disease progression.
- Good Safety Profile: The latest peer-reviewed data confirm that AMX0035's safety aligns with prior clinical findings, with all reported adverse events being mild or moderate, and no serious adverse events, bolstering confidence in its therapeutic potential.
- FDA Collaboration Progress: Amylyx is collaborating with the FDA to initiate a Phase 3 clinical trial for Wolfram syndrome, aiming to further validate AMX0035's efficacy and safety, demonstrating the company's commitment to future treatment options.
- Positive Patient Feedback: Qualitative interviews with participants reveal significant improvements in diabetes and vision issues, reflecting AMX0035's potential to enhance quality of life, which may attract increased investor interest.
See More
Amylyx Pharmaceuticals Q1 2026 Earnings Call Insights
- Clinical Trial Progress: In Q1 2026, Amylyx Pharmaceuticals randomized and dosed the last participant in the Phase III LUCIDITY trial, marking a significant milestone with top-line data expected next quarter, which will lay the groundwork for future drug commercialization.
- Accelerated Commercial Readiness: The company is actively advancing its NDA preparations, having begun drafting relevant sections, and plans to launch avexitide in 2027, reflecting a strong commitment to market demand and positive revenue outlook.
- Market Education Initiative: Amylyx plans to launch a disease state education campaign for PBH this summer to enhance market awareness, while strengthening marketing and commercial operations through key hires, which is expected to help the company secure a competitive position in the market.
- Strong Financial Position: As of the end of Q4, the company reported $279.8 million in cash and marketable securities, sufficient to fund operations into 2028, despite operating expenses of $43.8 million, indicating ongoing investment in clinical development to drive avexitide's commercialization.
See More
Amylyx Pharmaceuticals to Report Q1 2026 Financial Results on May 7
- Earnings Report Schedule: Amylyx Pharmaceuticals is set to release its Q1 2026 financial results on May 7, 2026, reflecting the company's ongoing commitment to transparency and investor communication.
- Management Conference Call: The senior management team will host a conference call at 8:00 a.m. ET to discuss the financial results and other company updates, which is expected to attract significant attention from investors and analysts.
- Participation Details: Investors can join the call by dialing +1 (888) 880-3330 for U.S. and Canada or +1 (646) 357-8766 for international participants, ensuring they call at least 10 minutes prior to the start time for smooth access.
- Webcast and Replay: The call will be available via live audio webcast under the “Events and Presentations” section of the company’s website, with a replay accessible for 90 days post-event, enhancing investor access to information.
See More
Halper Sadeh LLC Investigates Amylyx Management for Fiduciary Breaches
- Shareholder Rights Protection: Halper Sadeh LLC encourages shareholders of Amylyx Pharmaceuticals to contact the firm to discuss their rights and options, emphasizing the importance of timely action to protect shareholder interests.
- Legal Fee Arrangement: The firm commits to handling cases on a contingent fee basis, meaning shareholders will not incur any out-of-pocket legal fees or expenses, thereby lowering the barrier for shareholder participation.
- Corporate Governance Reforms: Long-term shareholders of Amylyx stock may have the opportunity to seek corporate governance reforms, fund returns, or court-approved financial incentive awards, aimed at enhancing transparency and accountability, ultimately increasing shareholder value.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide, focusing on combating securities fraud and corporate misconduct, with attorneys playing a crucial role in implementing corporate reforms and recovering funds for defrauded investors, showcasing their expertise in protecting investor rights.
See More
Amylyx Completes Last Participant Enrollment in LUCIDITY Trial for Avexitide
- Trial Enrollment Completion: Amylyx announced that the last participant has been randomized and dosed in the LUCIDITY trial, which enrolled a total of 78 participants, marking a significant milestone with topline data expected in Q3 2026, and a potential commercial launch of avexitide anticipated in 2027 if approved.
- Clinical Trial Design: The LUCIDITY trial is a 16-week, multicenter, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy of avexitide in reducing Level 2 and Level 3 hypoglycemic events in adults post-Roux-en-Y gastric bypass surgery, aligning with FDA-agreed primary outcomes.
- Early Data Support: Previous Phase 1 and Phase 2 trials demonstrated statistically significant reductions in hypoglycemic events with avexitide, indicating its potential to improve patient quality of life and address the urgent need for effective treatments in post-bariatric hypoglycemia.
- Urgent Market Need: Post-bariatric hypoglycemia (PBH) affects approximately 8% of patients who undergo weight-loss surgery, highlighting a significant unmet medical need; the development of avexitide could not only fill this gap but also alleviate the healthcare burden associated with this chronic condition.
See More
Amylyx Pharmaceuticals Updates on Avexitide LUCIDITY Trial Progress
- Trial Progress: Amylyx Pharmaceuticals' LUCIDITY trial is nearly fully enrolled and expects to release top-line results for avexitide in Q3; this 16-week randomized, placebo-controlled study aims to evaluate the drug's efficacy in treating post-bariatric hypoglycemia, highlighting the company's potential in an area lacking approved therapies.
- Drug Mechanism and Market Need: Avexitide, as a first-in-class GLP-1 receptor antagonist, targets approximately 160,000 U.S. patients suffering from post-bariatric hypoglycemia, with prior trials demonstrating significant reductions in hypoglycemic events and supporting its FDA Breakthrough Therapy designation, underscoring its market relevance.
- Efficacy and Data Support: In a Phase II trial, avexitide achieved a 64% reduction in hypoglycemic events at the highest tested dose, with a p-value of 0.003, showcasing its clinical effectiveness and bolstering investor confidence in the drug's potential.
- Future Development Plans: Amylyx is also pursuing a long-acting GLP-1 receptor antagonist, AMX0318, and has reported positive signals in its Wolfram syndrome program, indicating the company's strategic commitment to expanding its product pipeline and addressing unmet medical needs.
See More
